NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD
Taking everything into account, CERS scores 2 out of 10 in our fundamental rating. CERS was compared to 188 industry peers in the Health Care Equipment & Supplies industry. CERS has a bad profitability rating. Also its financial health evaluation is rather negative. CERS is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.16% | ||
ROE | -34.14% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 60.6% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.17 | ||
Debt/FCF | 12.67 | ||
Altman-Z | -4.81 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.32 | ||
Quick Ratio | 1.63 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 41.48 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:CERS (6/10/2025, 11:25:30 AM)
1.455
-0.01 (-1.02%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.35 | ||
P/FCF | 41.48 | ||
P/OCF | 32.51 | ||
P/B | 5.01 | ||
P/tB | 5.13 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.16% | ||
ROE | -34.14% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 60.6% | ||
FCFM | 3.24% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.17 | ||
Debt/FCF | 12.67 | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 120.84% | ||
Cap/Sales | 0.89% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.32 | ||
Quick Ratio | 1.63 | ||
Altman-Z | -4.81 |